MedWatch

Coloplast has a cost problem, says EVP of global operations

Increasing energy prices, wage inflation in Hungary, sky-high freight rates, and unchecked raw material expenses are costing Coloplast dearly. Now, the company’s head of global operations acknowledges he should have laid better plans.

Allan Rasmussen, executive vice president for global operations at Coloplast | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix

Rarely, if ever, have costs been as high as their current levels at medtech firm Coloplast, which is facing an energy price headwind so great that the company expects it to eat up 1 percentage point of its growth in 2022/2023, Danish business daily Børsen reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs